Highlights Clene Inc.

Equities

CLNN

US1856341029

Market Closed - Nasdaq Other stock markets 01:30:00 22/05/2024 am IST			5-day change	1st Jan Change
0.37 ^USD	-0.54%		-3.67%	+24.75%

08/05	Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M	MT
16/04	Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M	08/05	MT
Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	17/04	CI
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	15/03	CI
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
North American Morning Briefing : Stock Futures -2-	11/03	DJ
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs	22/02	CI
Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial	08/01	CI
US FDA finds Clene's trial data for ALS drug to be insufficient	21/12	RE
Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases	14/12	CI
Earnings Flash (CLNN) CLENE Reports Q3 Revenue $108M	07/11	MT
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
Clene Shares Jump After Being Awarded $45.1 Million Government Grant for Investigational ALS Drug	05/23/05	MT
Clene Awarded $45.1 Million Government Grant to Fund EAP for Investigational ALS Drug	05/23/05	MT
Earnings Flash (CLNN) CLENE Posts Q2 Revenue $269,000	14/23/14	MT
Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Clene Announces Publication of Phase 2 CNM-Au8Â® Clinical Data for the Treatment of ALS in LANCETâ€™s eClinicalMedicine	26/23/26	CI
Clene’S Cnm-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light Levels in the Healey Als Platform Trial	16/23/16	CI
North American Morning Briefing : Hopes Build for -3-	15/23/15	DJ
Clene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
Earnings Flash (CLNN) CLENE Posts Q1 Revenue $107,000	13/23/13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Clene Inc.

Equities

CLNN

US1856341029

Highlights

Filters